Table 1 Patient characteristics
From: Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry
Factor | Number of patients |
|---|---|
Number of patients | 115 |
Age (years) | Â |
≤ 50 | 39 (33,9%) |
> 05 | 76 (66,1%) |
Tumour | Â |
T1 | 33 (28,7%) |
T2-4 | 82 (71,3%) |
Nodal status | Â |
Positive | 56 (48,7%) |
Negative | 59 (51,3%) |
Grade | Â |
G1-2 | 63 (54,8%) |
G3 | 52 (45,2%) |
ER status | Â |
Positive | 60 (52,2%) |
Negative | 55 (47,8%) |
CK5/6 status (IHC) | Â |
Positive | 42 (36,5%) |
Negative | 73 (63,5%) |
CK14 status (IHC)* | Â |
Positive | 16 (14,0%) |
Negative | 98 (86,0%) |
CK17 status (IHC) | Â |
Positive | 29 (25,2%) |
Negative | 86 (74,8%) |
Adjuvant treatment | Â |
   Chemotherapy | 66 (57,4%) |
   Hormonotherapy | 82 (71,3%) |
   Radiotherapy | 21 (18,3%) |
   Missing data | 8 (7,0%) |